INDP Indaptus: רווח למניה בשנים עשר החודשים האחרונים

The current EPS TTM level for Indaptus Therapeutics (INDP) demonstrates volatility driven by patent disputes in the field of bacterial immunotherapy. Successes with the Decoy20 system and the prospects of combination therapy are creating positive momentum. However, capital shortages and safety risks during early-stage trials remain critical. The value of -6.95 is recorded as the baseline value determining the company's current financial reference point.

For Indaptus Therapeutics (INDP), net earnings per share determine the capitalization efficiency of its biopharmaceutical developments. This metric is calculated as the ratio of total annual net income to the number of common shares. By analyzing the fundamental TTM net earnings per share, an investor assesses the business's specific profitability. The stability of this indicator confirms the reliability of diversified biocomponent production chains. The trend of this indicator allows for timely portfolio rebalancing, minimizing the risk of drawdowns.